Immuneering Corp Files 2025 Proxy Statement
Ticker: IMRX · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: IMRX
TL;DR
IMRX proxy statement filed. Shareholders vote on company direction.
AI Summary
Immuneering Corporation filed its definitive proxy statement (DEF 14A) on April 21, 2025, for the fiscal year ending December 31, 2024. The filing provides details regarding the company's annual meeting and matters to be voted on by shareholders. The company is headquartered at 245 Main Street, Cambridge, MA.
Why It Matters
This filing is crucial for shareholders as it outlines the proposals and director nominations they will vote on, directly impacting the company's governance and future direction.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the proxy statement.)
- 20250421 — Filing Date (The date the definitive proxy statement was filed with the SEC.)
Key Players & Entities
- Immuneering Corporation (company) — Registrant
- 245 Main Street, Second Floor, Cambridge, MA 02142 (address) — Company Business and Mail Address
- 0001790340-25-000053 (filing_id) — Accession Number
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals, typically before an annual meeting.
When was Immuneering Corporation's fiscal year end?
Immuneering Corporation's fiscal year ends on December 31st, as indicated in the filing.
What is the company's primary business address?
The company's business address is 245 Main Street, Second Floor, Cambridge, MA 02142.
What is the SEC file number for Immuneering Corporation?
The SEC file number for Immuneering Corporation is 001-40675.
What is the accession number for this specific filing?
The accession number for this filing is 0001790340-25-000053.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding Immuneering Corp (IMRX).